BioOrbit, a UK-based developer of scalable hardware for large-scale protein crystallisation in microgravity, has raised £9.8M ($13.2M) in seed funding co-led by LocalGlobe and Breega. The platform produces uniform, stable protein crystals that enable conversion of intravenous hospital biologics into high-concentration, self-injectable at-home medicines. The capital will accelerate industrial deployment of its autonomous BOX manufacturing units aboard commercial space stations.
UK Space Biotech Secures Record Seed
The round marks the largest seed funding in in-space manufacturing history. It includes participation from Auxxo, Seedcamp, Type One Ventures, 7 percent Ventures, and angels. This comes amid a surge in space biomanufacturing, with Varda Space Industries raising $329M for orbital pharma production and SpacePharma securing $14M for satellite-based biotech labs. BioOrbit differentiates with scalable crystallization hardware targeting pharma reformulation, backed by recent UK Space Agency contracts.
Intravenous Biologics Strain Healthcare
Over 70% of top-selling drugs require hospital IV administration, driving high costs and limiting patient access, particularly in cancer care. Hospital overload contributes to NHS treatment target misses for complex therapies. Current Earth-based crystallization struggles with gravity-induced defects, resulting in viscous formulations unsuitable for self-injection. Microgravity addresses this by yielding superior, uniform crystals with reduced viscosity and enhanced stability.
BOX Units Enable Orbital Factories
BioOrbit's microwave-sized BOX units perform autonomous protein crystallisation in orbit, producing crystals for controlled-release, high-bioavailability drugs. Unlike experiment-focused rivals like Rhodium Scientific or Exobiosphere $2.2M seed, BioOrbit scales to manufacturing volumes for commercial pharma. The Baby BOX-E payload, set for SpaceX launch, tests re-entry survivability ahead of full production.
As Dr. Katie King, CEO, noted:
“Our focus from day one has been scale… It is a paradigm shift for cancer therapies.”
European VCs Bet on Regulation Wins
LocalGlobe and Breega co-led the round, signaling conviction in BioOrbit's regulatory roadmap with UK MHRA sandboxes. Additional backers like Seedcamp provide deeptech expertise. This investor mix blends mission-driven capital with growth scaling, validating the shift from ISS research to private station factories. Recent UK government £250k award to BioOrbit underscores policy tailwinds.
In-Space Manufacturing Scales Rapidly
The in-space manufacturing market stands at $968M in 2024, projected to reach $5.1B by 2032 at 23.2% CAGR. Space-based biopharma adds $5.29B with 11.4% growth through commercialization of LEO platforms like Starlab. Varda's sixth reentry mission in March 2026 proves product return feasibility, while UK firms like Space Forge share grants. BioOrbit targets the £1T antibody market by enabling at-home injectables, promising 90% cuts in hospital administration costs.
Founders Pioneer Space Pharma
Co-founders Dr. Katie King (CEO, ex-NASA intern) and Dr. Leonor Teles (oncology researcher) lead with domain expertise. New hires include Dr. Molly Mulligan as President BioOrbit Inc. and Dr. Ken Savin as Chief Science Officer. Advisor Paul Reichert brings 12 Space Shuttle and 4 ISS missions plus 4 US patents in space biologics. The 14-person team has outgrown two offices amid accelerator wins like Tech Nation Future Fifty and ESA Rising Stars.
ISS Launch Accelerates Deployment
Funds support Baby BOX-E's Q2 2026 ISS mission via SpaceX Transporter, the first orbital protein manufacturing payload. BioOrbit plans regulation-compliant clinical trials following UK Space Agency contracts. Team expansion targets engineering and operations roles, positioning for a full pharmaceuticals factory in space within 10 years.